New inhibitors of bacterial topoisomerase GyrA/ParC subunits

Current Opinion in Investigational Drugs

Volumn 10, Issue 8, 2009, Pages 804-810

  Black, Michael T ^a   Coleman, Kenneth ^a  

^a Novexel SA   (France)

Author keywords

Fluoroquinolone; Gyrase; Naphthyridone; Quinolone; Topoisomerase IV

Indexed keywords

ACH 702; AM 3005; CINOXACIN; CIPROFLOXACIN; CLOROBIOCIN; COUMAMYCIN; COUMARIN DERIVATIVE; DELAFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DW 286; FINAFLOXACIN; FLUORONAPHTHYRIDONE DERIVATIVE; GEMIFLOXACIN; JNJ Q2; LEVOFLOXACIN; MOXIFLOXACIN; NAPHTHYRIDONE DERIVATIVE; NEMONOXACIN; NORFLOXACIN; NOVOBIOCIN; NXL 101; OXOQUINOLINE CARBOXYLATE; OZENOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEMAFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIQUIDACIN; ZABOFLOXACIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CENTRAL NERVOUS SYSTEM DISEASE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART DISEASE; HEMOLYTIC UREMIC SYNDROME; HUMAN; LIVER TOXICITY; NONHUMAN; PHOTOTOXICITY; QT PROLONGATION; REVIEW; SEPSIS; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; TENDINITIS; TORSADE DES POINTES;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; HUMANS; PROTEIN SUBUNITS; QUINOLONES;

EID: 68649122111     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Sheehan G, Chew NSY: The history of quinolones. In: Fluoroquinolone Antibiotics. Ronald AR, Low DE (Eds), Birkhäuser Verlag, Basel, Switzerland (2003).
2. Bates AD, Maxwell A (Eds): DNA Topology. Oxford University Press, Oxford, UK (2005).
3. Bellon S, Parsons JD, Wei Y, Hayakawa K, Swenson LL, Charifson PS, Lippke JA, Aldape R, Gross CH: Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 Kilodaltons): A single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob Agents Chemother (2004) 48(5): 1856-1864.
4. Bryskier A, Klich M: Coumarin antibiotics: Novobiocin, coumermycin and clorobiocin. In: Antimicrobial Agents: Antibacterials and Antifungals. Bryskier A (Ed), ASM Press, Washington, DC, USA (2005):816-825.
5. Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage PR: 1, 8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Pharm Chem (1962) 91:1063-1065.
6. Laponogov I, Sohi MK, Veselkov DA, Pan X-S, Sawhney R, Thompson AW, McAuley KE, Fisher LM, Sanderson MR: Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol (2009) 16(6):667-669. • An account of the first tripartite structure, at ≥ Å resolution, of type IIA topoisomerase fragments in complex with quinolone and DNA.
7. Hooper DC: Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin Infect Dis (2001) 32 (Suppl 1):S9-S15.
8. Jacoby GA, Cattoir V, Hooper DC, Martínez-Martínez L, Nordmann P, Pascual A, Poirel L, Wang M: qnr gene nomenclature. Antimicrob Agents Chemother (2008) 52(7):2297-2299.
9. Tran JH, Jacoby GA, Hooper DC: Interaction of the plasmidencoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase. Antimicrob Agents Chemother (2005) 49(1): 118-125.
10. Tran JH, Jacoby GA, Hooper DC: Interaction of the plasmidencoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimicrob Agents Chemother (2005) 49(7):3050-3052.
11. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC: Fluoroquinolone-modifying enzyme: A new adaptation of a common aminoglycoside acetyltransferase. Nat Med (2006) 12(1):83-88.
12. Black MT, Stachyra T, Platel D, Girard A-M, Claudon M, Bruneau J-M, Miossec C: Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob Agents Chemother (2008) 52(9):3339-3349. • An account of the first non-quinolone/naphthyridone inhibitor to enter clinical trials.
13. van Bambeke F, Michot J-M, van Eldere J, Tulkens PM: Quinolones in 2005: An update. Clin Microbiol Infect (2005) 11(4):256-280. •• A concise review of not only structure-activity, but also of structure-toxicity and structure-pharmacokinetic relationships of fluoroquinolones.
14. Fluoroquinolone antimicrobial drugs [ciprofoxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin and generic ofloxacin)]. FDA, Silver Spring, MD, USA (2008). www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm084316.htm
15. Finch RG: The withdrawal of temafloxacin: Are there implications for other quinolones? Drug Saf (1993) 8(1):9-11.
16. Stahlmann R, Schwabe R: Safety profile of grepafioxacin compared with other fluoroquinolones. J Antimicrob Chemother (1997) 40 (Suppl A) :83-92.
17. Pfizer relabels antibiotic Trovan for serious infections. Doctor's Guide Publishing Ltd, Rockley, Barbados (1999). www.pslgroup.com/dg/1060B6.htm
18. Withdrawal of product: RAXAR (grepafloxacin HCl) 600 mg tablets, 400 mg tablets, and 200 mg tablets. FDA, Silver Springs, MD, USA (1999). www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a-tab5b.htm
19. Bradbury BJ, Pucci MJ: Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharm (2008) 8(5):574-581. •• An excellent summary of recent research advances in the field of bacterial topoisomerase inhibitor development.
20. Yun HJ, Min YH, Lim JA, Kang JW, Kim SY, Kim MJ, Jeong JH, Choi YJ, Kwon HJ, Jung YH, Shim MJ, Choi EC: In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic. Antimicrob Agents Chemother (2002) 46(9):3071-3074.
21. Morrow BJ, Goldschmidt R, Foleno B, Weidner-Wells M, Grant E, Xu X, Macielag M, Bush K: Potent in vitro activity of a new fluoroquinolone against ciprofloxacin-resistant S. pneumoniae. ICAAC (2007) 47:Abs F1-2122.
22. Foleno B, Morrow BJ, Wira E, Macielag M, Bush K: Broad spectrum in vitro activity of JNJ-Q2, a new fluoroquinolone. ICAAC (2008) 48:Abs F1-2033.
23. Morrow BJ, Foleno B, Goldschmidt R, He W, Amsler K, Macielag M, Bush K: iIn vitro activity of JNJ-Q2, a new fluoroquinolone, against susceptible and multi-drug resistant Streptococcus pneumoniae. ICAAC (2008) 48:Abs F1-2052.
24. Romero A, Grau T, Santos B, Albet C, Guerrero M, Schmid M, D'Aniello F, Tarrago C, Guglietta A: Non clinical safety evaluation of ozenoxacin (GF-001001-00): A novel non-fluorinated quinolone. ICAAC (2007) 47:Abs F1-2124.
25. Yamakawa T, Mitsuyama J, Hayashi K: In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother (2002) 49(3):455-465.
26. Tarrago C, Mendez EM, Sierra J, Palacin C, Guglietta A, Vila J: Ozenoxacin (GF-001001-00): In vitro antibacterial activity compared with other antibacterial agents against clinical isolates from wound infections and selection of resistant mutants. ICAAC (2007) 47:Abs F1-2123.
27. Levasseur P, Girard AM, Lowther J: Efficacy of oral NXL 101, a novel topoisomerase inhibitor, against fluroquinolonesusceptible (FQS) and-resistant (FQR) Streptococcus pneumoniae (Sp) strains in a mouse pneumonia model. ICAAC (2007) 47:Abs F1-2125.
28. Tarral A, Rangaraju M, Merdjan H, Girard AM, Delachaume C, Lowther J: Plasma bactericidal activity of NXL101 in healthy volunteers after single intravenous administrations of 50 to 700 mg. ICAAC (2007) 47:Abs A-808.
29. Pucci MJ, Thoma CL, Podos SD, Cheng J, Thanassi JA, Bradbury BJ, Deshpande M: In vitro and in vivo antibacterial activities of ACH-702 against gram-positive pathogens. ICAAC (2008) 48: Abs F1-2021.
30. Thanassi JA, Cheng J, Podos SD, Bradbury BJ, Deshpande M, Pucci MJ: Dual targeting of gyrase and topoisomerase IV by ACH-702 and mutation analysis in Staphylococcus aureus. ICAAC (2008) 48:Abs F1-2022.
31. Campion JJ, Titlow WB, Pucci MJ, Evans ME: Pharmacokinetic/ pharmacodynamic (PK/PD) factors influencing emergence of resistance to ACH-702 in methicillin-and quinolone-resistant Staphylococcus aureus (MQRSA) in an in vitro Model (IVM). ICAAC (2008) 48:Abs F1-2024.
32. Podos SD, Cheng J, Thanassi JA, Deshpande M, Pucci MJ: Bactericidal activity of ACH-702 against non-dividing Staphylococci. ICAAC (2008) 48:Abs F1-2023.
33. Ebisu H, Yamaguchi Y, Ueda R, Kishii R, Takei M: AM-3005, a novel mutilin-quinolone hybrid antibiotic with potent activity against MRSA. ICAAC (2008) 48:Abs F1-2031.
34. Yamaguchi Y, Ebisu H, Ueda R, Kishii R, Takei M: AM-3005 (AM), a novel mutilin-quinolone hybrid, possesses potent inhibitory activity against protein synthesis with a type II topoisomerase inhibition. ICAAC (2008) 48:Abs F1-2032.
35. Charifson PS, Grillot AL, Grossman TH, Parsons JD, Badia M, Bellon S, Deininger DD, Drumm JE, Gross CH, LeTiran A, Liao Y et al: Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem (2008) 51(17): 5243-5263.
36. Illingworth RN, Uria-Nickelsen M, Bryant J, Eakin A: Novel DNA gyrase inhibitors: Microbiological characterization and in vivo efficacy of pyrrolamides. ICAAC (2008) 48:Abs F1-2028.
37. Kresken M, Kerber-Irrgang B, Labischinski H, Stubbings W: Effect of pH on the in vitro activity of finafloxacin against gramnegative and gram-positive bacteria. ICAAC (2008) 48: Abs F1-2037.
38. Endermann R, Ladel C, Stubbings W, Labischinski H: Pharmacokinetics (PK) and in vivo efficacy of oral finafloxacin (FIN) and comparators in rodent models of systemic infection. ICAAC (2008) 48:Abs F1-2044.
39. Endermann R, Ladel C, Stubbings W, Labischinski H: In vivo efficacy of finafloxacin (FIN) in difficult to treat animal models of infection. ICAAC (2008) 48:Abs F1-2045.
40. Patel H, Andresen A, Vente A, Heilmann HD, Seiberling M, Lopez L, Pokorny R, Labischinski H: A phase I study to determine safety, tolerability and pharmacokinetics (PK) of finafloxacin (FIN) in healthy subjects. ICAAC (2008) 48:Abs F1-2048.
41. Kwon AR, Min YH, Ryu JM, Choi DR, Shim MJ, Choi EC: In vitro and in vivo activities of DW-224a, a new fluoroquinolone antibiotic agent. J Antimicrob Chemother (2006) 58(3):684-688.
42. Louie A, Liu W, Bhavnani SM, Wikler M, Ambrose PG: Efficacy of dose-ranging and front-loading Zabofloxacin (Zabo) for Streptococcus pneumoniae (Spn) in an in vitro pharmacodynamic (PD) model. ICAAC (2008) 48:Abs A-046.
43. Jones R, Ambrose P, Wikler M: Definition of wildtype MIC distributions for targeted species for determination of optimal dosing for zabofloxacin, a novel fluoronaphthyridone. ECCMID (2008) 18:Abs P553.
44. Ambrose P, Bhavnani S, Jones R, Wikler M: Analyses supporting phase 2 clinical trial dose selection for zabofloxacin in community-acquired pneumonia. ECCMID (2008) 18:Abs P1261.
45. Pacific Beach Biosciences Inc: Pacific Beach BioSciences and Dong Wha Pharmaceuticals sign exclusive license agreement to develop and commercialize zabofloxacin (PB-101, DW-224a). Press Release (2007): August 10.
46. Jones ME, Critchley IA, Karlowsky JA, Blosser-Middleton RS, Schmitz FJ, Thornsberry C, Sahm DF: In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Staphylococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV. Antimicrob Agents Chemother (2002) 46(6):1651-1657.
47. Zhanel GG, Laing N, Decorby M, Nichol K, King CHR, Adam H, Hoban DJ: Activity of nemonoxacin, an investigational C8-methoxy non-fluorinated quinolone against gram-positive cocci obtained from Canadian hospitals: CANWARD 2007. ICAAC (2008) 48:Abs F1-2057.
48. Pankuch GA, Kosowska-Shick K, King CR, Appelbaum PC: Comparative antistaphylococcal activity of nemonoxacin, a novel broad-spectrum quinolone. ICAAC (2008) 48:Abs C1-189.
49. Laing N, Decorby M, Nichol K, King CHR, Adam H, Hoban DJ, Zhanel GG: Activity of nemonoxacin, an investigational C8-methoxy non-fluorinated quinolone, against gram-negative bacilli obtained from Canadian hospitals: CANWARD 2007. ICAAC (2008) 48:Abs C1-1957.
50. Hsu CH, Lin L, Leunk R, Reichart D: In vivo efficacy of nemonoxacin in a mouse pulmonary infection model. ICAAC (2008) 48:Abs B-056.
51. Hsu CH, Lin L, Leunk R, Reichart D: In vivo efficacy of nemonoxacin in a mouse protection model. ICAAC (2008) 48: Abs B-1005.
52. Lin L, Chiu KM, Chung TK: Single-dose safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum non-fluorinated quinolone, in healthy volunteers. IDSA (2007) 45:Abs 439.
53. Zhang H, Chiu KM, Chung TK, Tan HT, Lin L: Multiple-dose Study to assess the safety, tolerability and pharmacokinetics of nemonoxacin (TG-873870) in healthy volunteers. IDSA (2007) 45:Abs 440.
54. TaiGen Biotechnology Co Ltd: TaiGen announces positive data from the phase II study of nemonoxacin (TG-873870) in community-acquired pneumonia. Press Release (2008): April 07.
55. Dalvie DK, Khosla N, Vincent J: Excretion and metabolism of trovafloxacin in humans. Drug Metab Dispos (1997) 25(4): 423-427.
56. Delafloxacin (RX-3341). Rib-X Pharmaceuticals Inc, New Haven, CT, USA (2009). www.rib-x.com/pipeline/rx-3341
57. Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD: In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother (2004) 48(7):2771-2777.
58. Rib-X Pharmaceuticals Inc: Rib-X Pharmaceuticals reports positive top-line results from phase 2 study of delafloxacin. Press Release (2008): December 08.
59. O'Riordan W, Babazadeh S, Keech R, Manos P, Mascolo M, Mehra P, Surber J, Hopkins S and Burak E: Results of a phase 2 study comparing two doses of delafloxacin to tigecycline in adults with complicated skin and skin structure infections. ECCMID (2009) 19:Abs P-1794.
60. McGhee P, Appelbaum PC: Comparative activity of WCK 771 against S. aureus with raised vancomycin and daptomycin MICs and other resistotypes. ICAAC (2007) 47:Abs F1-2129.
61. Salat DP, Baxi NM, Bhattacharya AK: Safety and efficacy of WCK 771 compare to vancomycin and linezolid in MRSA. Annual Conference of Association of Physicians of India, National Capital Region, India (2009).